Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ADC Therapeutics SA (ADCT)

ADC Therapeutics expects $21 million Q3 ZYNLONTA revenue; reports ASH trial data

Mixed Impact 3 of 5 earnings Written later

ADC Therapeutics released preliminary third-quarter 2026 figures and new ZYNLONTA trial data to be presented at the December 2026 ASH meeting. The company expects net product revenue of $21 million for the quarter ended September 30, 2026, and reported cash and cash equivalents of $189.2 million as of that date, but the figures are unaudited and not finalized. The filing also notes that the FDA raised serious concerns about the LOTIS-5 trial results at a recent pre-sBLA meeting.

Key points

  • Expected net product revenue from ZYNLONTA of $21 million for the quarter ended September 30, 2026; the company has not finalized these results.
  • Cash and cash equivalents of $189.2 million as of September 30, 2026; the company cites an expected cash runway into 2029.
  • LOTIS-7 Phase 1b study showed an 88.7% overall response rate and 75.3% complete response rate among 97 efficacy-evaluable patients.
  • The filing cites FDA concerns about LOTIS-5 trial results raised at a recent pre-sBLA submission meeting.

The filing

CompanyADC Therapeutics SA (ADCT)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:00 PM ET
Accession number0000950103-26-016945

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.